FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1407 May 23, 1996 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kay, R.

To the Editor: The conclusion by Kay et al. (Dec. 14 issue)¹ that low-molecular-weight heparin improves the outcomes of patients with acute ischemic stroke can be questioned for two reasons. First, aspirin should have been administered to the patients in the control group, because aspirin is regarded as standard therapy in this clinical situation.² Without the administration of aspirin in the control group, it cannot be concluded that nadroparin had a significant effect beyond the current standard of care.

Second, there was a high rate of complications in the placebo group after the treatment period, including an increased number of . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.